HC Wainwright Forecasts Agenus’ Q4 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at HC Wainwright boosted their Q4 2024 earnings per share estimates for Agenus in a research report issued to clients and investors on Thursday, December 5th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings per share of ($2.62) for the quarter, up from their prior forecast of ($2.88). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($6.85) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($6.45) EPS and FY2028 earnings at ($6.70) EPS.

Several other analysts also recently weighed in on AGEN. B. Riley reduced their target price on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.00.

Agenus Trading Up 14.0 %

Shares of Agenus stock opened at $3.58 on Monday. The company has a fifty day simple moving average of $3.98 and a 200-day simple moving average of $7.78. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The stock has a market cap of $83.98 million, a price-to-earnings ratio of -0.32 and a beta of 1.24.

Institutional Investors Weigh In On Agenus

Institutional investors have recently modified their holdings of the company. Point72 DIFC Ltd acquired a new position in Agenus during the second quarter worth about $51,000. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the 3rd quarter worth approximately $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Agenus during the 2nd quarter valued at $106,000. HighTower Advisors LLC grew its holdings in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Agenus by 52.0% during the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after buying an additional 9,422 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.